Next Article in Journal
New Insights into Human Cytomegalovirus pUL52 Structure
Next Article in Special Issue
Recent Advances in Developing Treatments of Kaposi’s Sarcoma Herpesvirus-Related Diseases
Previous Article in Journal
Adeno-Associated Vector-Delivered CRISPR/SaCas9 System Reduces Feline Leukemia Virus Production In Vitro
Previous Article in Special Issue
Amenamevir, a Helicase-Primase Inhibitor, for the Optimal Treatment of Herpes Zoster
Review

Rational Design of Live-Attenuated Vaccines against Herpes Simplex Viruses

1
Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA
2
Division of Biotechnology and Molecular Medicine, Louisiana State University, Baton Rouge, LA 70803, USA
3
Rational Vaccines Inc., Woburn, MA 01801, USA
*
Authors to whom correspondence should be addressed.
Academic Editor: Barry J. Margulies
Viruses 2021, 13(8), 1637; https://doi.org/10.3390/v13081637
Received: 3 July 2021 / Revised: 9 August 2021 / Accepted: 13 August 2021 / Published: 18 August 2021
(This article belongs to the Special Issue Anti-herpesvirus Drugs and Vaccines)
Diseases caused by human herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) affect millions of people worldwide and range from fatal encephalitis in neonates and herpes keratitis to orofacial and genital herpes, among other manifestations. The viruses can be shed efficiently by asymptomatic carriers, causing increased rates of infection. Viral transmission occurs through direct contact of mucosal surfaces followed by initial replication of the incoming virus in skin tissues. Subsequently, the viruses infect sensory neurons in the trigeminal and lumbosacral dorsal root ganglia, where they are primarily maintained in a transcriptionally repressed state termed “latency”, which persists for the lifetime of the host. HSV DNA has also been detected in other sympathetic ganglia. Periodically, latent viruses can reactivate, causing ulcerative and often painful lesions primarily at the site of primary infection and proximal sites. In the United States, recurrent genital herpes alone accounts for more than a billion dollars in direct medical costs per year, while there are much higher costs associated with the socio-economic aspects of diseased patients, such as loss of productivity due to mental anguish. Currently, there are no effective FDA-approved vaccines for either prophylactic or therapeutic treatment of human herpes simplex infections, while several recent clinical trials have failed to achieve their endpoint goals. Historically, live-attenuated vaccines have successfully combated viral diseases, including polio, influenza, measles, and smallpox. Vaccines aimed to protect against the devastation of smallpox led to the most significant achievement in medical history: the eradication of human disease by vaccination. Recently, novel approaches toward developing safe and effective live-attenuated vaccines have demonstrated high efficacy in various preclinical models of herpetic disease. This next generation of live-attenuated vaccines has been tailored to minimize vaccine-associated side effects and promote effective and long-lasting immune responses. The ultimate goal is to prevent or reduce primary infections (prophylactic vaccines) or reduce the frequency and severity of disease associated with reactivation events (therapeutic vaccines). These vaccines’ “rational” design is based on our current understanding of the immunopathogenesis of herpesviral infections that guide the development of vaccines that generate robust and protective immune responses. This review covers recent advances in the development of herpes simplex vaccines and the current state of ongoing clinical trials in pursuit of an effective vaccine against herpes simplex virus infections and associated diseases. View Full-Text
Keywords: herpes simplex virus; herpesviruses; live-attenuated vaccines; vaccines herpes simplex virus; herpesviruses; live-attenuated vaccines; vaccines
MDPI and ACS Style

Stanfield, B.A.; Kousoulas, K.G.; Fernandez, A.; Gershburg, E. Rational Design of Live-Attenuated Vaccines against Herpes Simplex Viruses. Viruses 2021, 13, 1637. https://doi.org/10.3390/v13081637

AMA Style

Stanfield BA, Kousoulas KG, Fernandez A, Gershburg E. Rational Design of Live-Attenuated Vaccines against Herpes Simplex Viruses. Viruses. 2021; 13(8):1637. https://doi.org/10.3390/v13081637

Chicago/Turabian Style

Stanfield, Brent A., Konstantin G. Kousoulas, Agustin Fernandez, and Edward Gershburg. 2021. "Rational Design of Live-Attenuated Vaccines against Herpes Simplex Viruses" Viruses 13, no. 8: 1637. https://doi.org/10.3390/v13081637

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop